Besides learning
a lot and having fun, we achieved something great this year!
Check it out!
Difference between revisions of "Team:Freiburg"
JanaNeuber (Talk | contribs) |
|||
| Line 514: | Line 514: | ||
<div class="cool_image_blink element1"> | <div class="cool_image_blink element1"> | ||
| − | <div class="cool_content cool_text_blink link_trigger" href= | + | <div class="cool_content cool_text_blink link_trigger" href="https://2017.igem.org/Team:Freiburg/Achievements" title=""> |
<div class="text"> | <div class="text"> | ||
Besides learning <br> a lot and having fun, we achieved something great this year! | Besides learning <br> a lot and having fun, we achieved something great this year! | ||
| Line 522: | Line 522: | ||
</div> | </div> | ||
</div> | </div> | ||
| − | <div class="cool_header"><a href= | + | <div class="cool_header"><a href="https://2017.igem.org/Team:Freiburg/Achievements">Achievements</a></div> |
</div> | </div> | ||
</li> | </li> | ||
Revision as of 20:21, 31 October 2017
-
Find out more
about the Freiburg 2017 Team and its members! -
To make our approach safer, we are using a 2-input AND gate. Have a look!
-
We generated
stable cell lines, a gene knockdown, characterized several promoters and much more! -
To better
understand our AND gate, we modeled gene expression within our genetic circuit. -
To hear thoughts about our project check out our survey and interviews with experts working on the field!
Abstract
A new approach to cancer treatment is the chimeric antigen receptor (CAR) therapy, which shows promising results fighting tumors in clinical trials. It consists of autologous isolated T cells modified with a chimeric receptor based on the T-cell receptor combined with the recognition domain of an antibody. Upon reinjection, CAR T cells exhibit cytotoxicity with high affinity towards cells displaying the antigen. However, clinical trials have shown that as tumor antigens are not solely expressed on tumor cells, but also on healthy tissues, grave off-target effects like the Graft-versus-Host-Disease may occur. In order to avoid such side-effects, we engineer CAR T cell lines specifically activated by factors of the tumor microenvironment. Controlled by a genetic AND gate system the T cells need two input signals in order to express CAR. This would allow highly localized cytotoxic activity of T cells and provide safer cell-based cancer immunotherapy especially for solid tumors.
